DaVita (NYSE:DVA) Stock Rating Cut to “Hold” at Wall Street Zen

Wall Street Zen lowered shares of DaVita (NYSE:DVA) from a buy rating to a hold rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.

Several other research firms have also recently weighed in on DVA. Zacks Research cut shares of DaVita from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Raymond James Financial set a $220.00 price objective on DaVita in a report on Friday, August 7th. TD Cowen upgraded DaVita from a “hold” rating to a “buy” rating and increased their price objective for the stock from $201.00 to $220.00 in a research report on Friday, August 7th. Barclays raised their target price on DaVita from $218.00 to $224.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 5th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $265.00 target price on shares of DaVita in a research report on Wednesday, August 5th. Three research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $233.43.

DaVita Trading Up 2.1%

Shares of DVA stock opened at $178.29 on Friday. The company’s 50-day moving average price is $194.23 and its 200-day moving average price is $187.67. The stock has a market cap of $11.38 billion, a price-to-earnings ratio of 14.59, a PEG ratio of 0.46 and a beta of 0.83. DaVita has a twelve month low of $101.00 and a twelve month high of $247.49.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.88 by $0.14. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The firm had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.50 billion. During the same quarter in the prior year, the firm posted $2.95 earnings per share. DaVita’s quarterly revenue was up 5.2% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities research analysts predict that DaVita will post 14.57 EPS for the current year.

Hedge Funds Weigh In On DaVita

A number of hedge funds have recently made changes to their positions in DVA. Envestnet Portfolio Solutions Inc. purchased a new position in shares of DaVita during the second quarter worth $268,000. Sequoia Financial Advisors LLC raised its holdings in shares of DaVita by 6.2% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 2,791 shares of the company’s stock valued at $621,000 after buying an additional 164 shares during the period. IPG Investment Advisors LLC acquired a new position in DaVita during the 2nd quarter worth about $1,938,000. Integrated Wealth Concepts LLC lifted its stake in DaVita by 164.5% during the 2nd quarter. Integrated Wealth Concepts LLC now owns 10,530 shares of the company’s stock worth $2,343,000 after acquiring an additional 6,549 shares in the last quarter. Finally, NewEdge Advisors LLC boosted its holdings in DaVita by 66.4% during the 2nd quarter. NewEdge Advisors LLC now owns 361 shares of the company’s stock valued at $80,000 after acquiring an additional 144 shares during the period. Hedge funds and other institutional investors own 90.12% of the company’s stock.

About DaVita

DaVita Inc (NYSE: DVA) is a healthcare company focused primarily on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis services for people with chronic kidney failure, including in-center hemodialysis and home-based dialysis options. Its services also include clinical care, education, nutrition support and other resources intended to help patients manage kidney disease.

DaVita also provides broader kidney-care services, including chronic kidney disease management, care coordination and support for patients who may be candidates for kidney transplantation.